retatrutide success stories The Guide for Canadians (2026) I’m not a prescriber —

Conclusion The potential for GLP-1 RAs to serve as a therapeutic option in AS presents an exciting avenue for further exploration, particularly given the unmet need for treatments that slow the progression of kidney function decline in this patient population

The rationale is that glucagon-receptor agonism increases energy expenditure and promotes hepatic lipid mobilization, effectively adding a burn component on top of the eat less component supplied by GLP-1

We observed the downregulation of many, mostly humoral, innate immune response genes upon UQCR-C1 knockdown

For weight loss, some may increase to 2.4 mg weekly (Wegovy formulation)

Yes, but only slightly and inconsistently

This in turn may mitigate the risks associated with off-brand versions of GLP-1 receptor agonists